195 related articles for article (PubMed ID: 18492024)
21. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.
Tan HK; James PD; Wong F
Dig Dis Sci; 2016 Oct; 61(10):3084-3092. PubMed ID: 27048451
[TBL] [Abstract][Full Text] [Related]
22. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.
Rai N; Singh B; Singh A; Vijayvergiya R; Sharma N; Bhalla A; Singh V
Liver Int; 2017 Mar; 37(3):406-414. PubMed ID: 27614145
[TBL] [Abstract][Full Text] [Related]
23. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Hanafy AS; Hassaneen AM
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1455-1461. PubMed ID: 27622998
[TBL] [Abstract][Full Text] [Related]
24. Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents.
Esrailian E; Runyon BA
Nat Clin Pract Nephrol; 2006 Mar; 2(3):169-72. PubMed ID: 16932415
[TBL] [Abstract][Full Text] [Related]
25. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Pomier-Layrargues G; Paquin SC; Hassoun Z; Lafortune M; Tran A
Hepatology; 2003 Jul; 38(1):238-43. PubMed ID: 12830007
[TBL] [Abstract][Full Text] [Related]
26. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Solà E; Solé C; Simón-Talero M; Martín-Llahí M; Castellote J; Garcia-Martínez R; Moreira R; Torrens M; Márquez F; Fabrellas N; de Prada G; Huelin P; Lopez Benaiges E; Ventura M; Manríquez M; Nazar A; Ariza X; Suñé P; Graupera I; Pose E; Colmenero J; Pavesi M; Guevara M; Navasa M; Xiol X; Córdoba J; Vargas V; Ginès P
J Hepatol; 2018 Dec; 69(6):1250-1259. PubMed ID: 30138685
[TBL] [Abstract][Full Text] [Related]
27. Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial.
Degoricija V; Zjacic-Rotkvic V; Marout J; Sefer S; Troskot B
Croat Med J; 2003 Apr; 44(2):178-86. PubMed ID: 12698509
[TBL] [Abstract][Full Text] [Related]
28. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
29. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.
Sersté T; Francoz C; Durand F; Rautou PE; Melot C; Valla D; Moreau R; Lebrec D
J Hepatol; 2011 Oct; 55(4):794-9. PubMed ID: 21354230
[TBL] [Abstract][Full Text] [Related]
30. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.
Alessandria C; Elia C; Mezzabotta L; Risso A; Andrealli A; Spandre M; Morgando A; Marzano A; Rizzetto M
Dig Liver Dis; 2011 Nov; 43(11):881-6. PubMed ID: 21741331
[TBL] [Abstract][Full Text] [Related]
31. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
Yosry A; Soliman ZA; Eletreby R; Hamza I; Ismail A; Elkady MA
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):345-351. PubMed ID: 30312183
[TBL] [Abstract][Full Text] [Related]
32. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
33. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
34. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
Salerno F; Cazzaniga M; Merli M; Spinzi G; Saibeni S; Salmi A; Fagiuoli S; Spadaccini A; Trotta E; Laffi G; Koch M; Riggio O; Boccia S; Felder M; Balzani S; Bruno S; Angeli P;
J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
[TBL] [Abstract][Full Text] [Related]
36. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
Duvoux C; Zanditenas D; Hézode C; Chauvat A; Monin JL; Roudot-Thoraval F; Mallat A; Dhumeaux D
Hepatology; 2002 Aug; 36(2):374-80. PubMed ID: 12143045
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study.
Lata J; Marecek Z; Fejfar T; Zdenek P; Brůha R; Safka V; Hůlek P; Hejda V; Dolina J; Stehlík J; Tozzi I
Hepatogastroenterology; 2007; 54(79):1930-3. PubMed ID: 18251131
[TBL] [Abstract][Full Text] [Related]
38. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.
Moreau R; Valla DC; Durand-Zaleski I; Bronowicki JP; Durand F; Chaput JC; Dadamessi I; Silvain C; Bonny C; Oberti F; Gournay J; Lebrec D; Grouin JM; Guémas E; Golly D; Padrazzi B; Tellier Z
Liver Int; 2006 Feb; 26(1):46-54. PubMed ID: 16420509
[TBL] [Abstract][Full Text] [Related]
39. Albumin infusion fails to restore circulatory function following paracentesis of tense ascites as assessed by beat-to-beat haemodynamic measurements.
Schneditz D; Bachler I; Stadlbauer V; Stauber RE
Int J Clin Pract; 2008 Dec; 62(12):1851-7. PubMed ID: 17927765
[TBL] [Abstract][Full Text] [Related]
40. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
